NMN Regulatory Status in EU, US, UK, and Germany (2024-2026 Timeline)

Sophie Chabloz on July 30, 2026

NMN Regulatory Status in EU, US, UK, and Germany (2024-2026 Timeline)

By Sophie Chabloz | May 2026

NMN's regulatory story has shifted faster than almost any other supplement category in the past three years. If you've tried to buy NMN online and seen "out of stock," "shipping restrictions apply," or different prices in different markets, regulation is the reason. Two developments have reshaped the picture in the last year: the US FDA reversed its position on NMN in late 2025, and EFSA issued a positive safety opinion in the EU in 2026. This piece sets out where each major jurisdiction stands as of mid-2026, what changed, and what's likely to come next. It's for anyone trying to make sense of why their NMN is harder, or easier, to access than it was last year.

In this article:

  • Why NMN's regulatory status is unusually complicated

  • United States: from 2022 exclusion to 2025 reversal

  • European Union: the novel food question

  • United Kingdom: post-Brexit divergence

  • Germany: BVL guidance and the practical situation

  • Switzerland: where AVEA operates

  • What this means for the next 12-24 months

  • Where to go next

Why NMN's regulatory status is unusually complicated

Most supplements fall cleanly into one of two regulatory buckets. Either the molecule has been used in food long enough to have grandfathered status, or it's a vitamin or mineral with a clear classification. NMN belongs to neither.

NMN is a naturally occurring intermediate in human metabolism, present in small quantities in foods like broccoli, avocado, and edamame. But it hasn't been consumed at supplement-level doses historically, and several pharmaceutical companies have studied it as an investigational drug. That combination, food-natural origin plus drug-investigation history, is exactly what triggers the most uncertain regulatory category in most jurisdictions.

The result is a patchwork. Different jurisdictions have arrived at different answers, often inconsistent with each other and sometimes inconsistent within a single regulator's own pronouncements over time.

United States: from 2022 exclusion to 2025 reversal

The US story has been the most public, and it has now turned. In 2022, the FDA determined that NMN is excluded from the dietary supplement definition under section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act, on the basis that it had been authorised for investigation as a new drug before being marketed as a supplement. The practical effect was that NMN sold as a dietary supplement was, in the FDA's view, mislabelled, and several ingredient notifications were rejected.

That position held until 2025. After a sustained challenge from the Natural Products Association, including a citizen petition and a federal lawsuit, the FDA reversed course. In two letters dated 29 September 2025, the agency confirmed that NMN is not excluded from the dietary supplement definition and is lawful for use in supplements. Its reasoning turned on the "race to market" provision: the FDA concluded there was sufficient evidence that NMN had been marketed as a dietary supplement, as early as 2017, before it was authorised for drug investigation. In December 2025, the FDA followed up with letters to ingredient suppliers reinstating their earlier new dietary ingredient (NDI) notifications.

The reversal removes the categorical ban, but it doesn't remove every requirement. NMN is still treated as a new dietary ingredient, so companies must satisfy NDI premarket notification requirements before marketing it, unless they source from a supplier whose notification the FDA has already acknowledged. For US consumers, the upshot is that NMN is now lawfully available as a dietary supplement from compliant sellers, after nearly three years of uncertainty.

European Union: the novel food question

Under EU law, ingredients not consumed at meaningful levels in the European market before 15 May 1997 require novel food authorisation. NMN, despite occurring naturally in trace amounts in food, hasn't historically been consumed at supplement doses in the EU, so it falls squarely in the novel food category. An early application was closed without authorisation in 2022, and since then several parties have applied, with EFSA carrying out the safety assessment and the European Commission responsible for authorisation and the Union list.

The picture moved significantly in 2026. In May 2026, EFSA published a positive safety opinion on beta-NMN, concluding that intakes up to 300 mg per day are safe for the general adult population, excluding pregnant and lactating women, when used as a source of niacin in food supplements. That opinion related to a specific applicant's ingredient, and it is the clearest signal yet that NMN is heading toward EU authorisation.

What hasn't happened yet is formal authorisation. The European Commission and member states now review EFSA's opinion and decide on adding NMN to the Union list, a step that typically follows within several months of a positive opinion and is initially specific to the applicant, with a period of data protection. Until that happens, NMN remains an unauthorised novel food across the EU, and other producers' NMN stays under novel food restrictions. In practice, member states have taken different enforcement approaches during this interim: some tolerate sales pending authorisation, others act against specific brands. For EU consumers, expect the position to become clearer over the course of 2026 and into 2027.

United Kingdom: post-Brexit divergence

The UK runs its own novel food regime through the Food Standards Agency (FSA), which has diverged from the EU since Brexit. NMN is treated as a novel food in Great Britain and sits under FSA assessment rather than full authorisation; applications are in the system, but none has yet been authorised. Under transitional arrangements, products lawfully on the market before the regulation's 1 January 2018 cut-off have been able to keep selling while assessment proceeds, whereas new entrants face the full approval pathway.

In practice, NMN is widely sold across Great Britain and monitored by the FSA for safety, quality, and labelling, which makes the UK somewhat more permissive in practice than the EU on emerging categories like this one. Northern Ireland is the exception: under the Northern Ireland arrangements it continues to follow EU rules, so NMN is unauthorised there in the same way it is across the EU.

Germany: BVL guidance and the practical situation

Germany deserves its own section because it's the largest supplement market in Europe and has historically taken some of the strictest readings of EU food law. The BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit) is the competent federal authority for novel foods, and it has issued guidance on handling unauthorised novel foods, which under the EU framework may not be sold until authorised. NMN falls under that framework, so it isn't lawfully marketable as a food or supplement in Germany while EU authorisation is pending.

That hasn't removed NMN from the German market. It remains available online, largely in a legal grey zone, but the classification has affected which retailers are willing to carry it, and German consumer-protection bodies have been active against brands they consider non-compliant. Enforcement itself sits with the state (Länder) authorities.

Switzerland: where AVEA operates

Switzerland is not in the EU and runs its own food law. Food supplements are regulated as foods by the Federal Food Safety and Veterinary Office (FSVO, known by its German acronym BLV), with enforcement carried out by the cantonal authorities. Swissmedic, the medicines regulator, is involved only where a product would count as a medicine rather than a supplement.

Switzerland also has its own novel food system, set out in the Ordinance on Novel Foods, separate from the EU's EFSA and Commission process. Most supplements can be placed on the market under the manufacturer's own responsibility without prior authorisation, but novel foods are an exception and require FSVO authorisation before sale. Where a novel food is already authorised in the EU, it can generally be sold in Switzerland under the same conditions without a separate Swiss authorisation.

This is the framework AVEA, headquartered in Zug, operates within. The AVEA NMN supplement uses Longevir, the only NMN currently manufactured in Europe (Borealis Pharma, the Netherlands), produced by enzymatic synthesis and verified at greater than 99 percent purity, with every batch independently tested in a Swiss laboratory before release. We cover the broader sourcing context at https://insights.avea-life.com/longevity/what-is-nmn-and-how-does-it-work/.

What this means for the next 12-24 months

Two of the changes readers were waiting for have now landed: EFSA's positive opinion in the EU and the FDA's reversal in the US. The next 12 to 24 months are likely to bring three further shifts.

First, formal EU authorisation. Following EFSA's May 2026 opinion, the European Commission and member states are expected to move toward adding NMN to the Union list, initially on an applicant-specific basis with data protection. That would give at least some NMN products a clear, lawful route to the EU market for the first time.

Second, consolidation in the US. With NMN confirmed as a lawful dietary ingredient, the open questions shift to NDI notifications, quality, and how consistently the drug-preclusion clause is applied to the next longevity ingredient in line.

Third, quality standards will keep separating the market. As regulators ask for more documentation, the gap between rigorously manufactured, third-party-tested NMN and grey-market product widens. Consumers who choose verified NMN will face fewer surprises than those buying on price alone.

For now, wherever you live, the most defensible choice is a brand that operates from a compliant jurisdiction, uses verified pharmaceutical-grade NMN with batch-level testing, and is transparent about sourcing.

Where to go next

To understand what separates a high-quality NMN from a low-quality one beyond the regulatory categories, "How to choose a high-quality NMN supplement: purity, sourcing, third-party testing" is the practical buyer's guide. To compare NMN and NR on regulatory grounds among others, "NMN vs NR (nicotinamide riboside): the complete comparison" sets them side by side. And "NAD+ Decline and How to Restore It" gives the broader frame.

Related reading from AVEA insights

Leave a Reply

Your email address will not be published. Required fields are marked *